vs
LifeStance Health Group, Inc.（LFST）与Strata Critical Medical, Inc.（SRTA）财务数据对比。点击上方公司名可切换其他公司
LifeStance Health Group, Inc.的季度营收约是Strata Critical Medical, Inc.的16.8倍（$382.2M vs $22.7M）。Strata Critical Medical, Inc.同比增速更快（361.2% vs 17.4%）。LifeStance Health Group, Inc.自由现金流更多（$46.6M vs $-10.2M）。过去两年LifeStance Health Group, Inc.的营收复合增速更高（12.8% vs -33.6%）
LifeStance Health Group是美国的门诊行为健康服务提供商，支持线下面诊与远程诊疗两种服务模式，业务涵盖心理咨询、精神科诊疗、经颅磁刺激（TMS）以及氯胺酮治疗等。该公司曾多次因劳动违规、客户信息泄露及误导投资者相关问题遭遇诉讼。
Strata Critical Medical, Inc.是一家医疗技术企业，设计、生产及销售用于重症监护、麻醉及外科场景的一次性医疗用品，主要服务北美及部分欧洲地区的医疗机构，专注提升患者安全与临床诊疗效率。
LFST vs SRTA — 直观对比
营收规模更大
LFST
是对方的16.8倍
$22.7M
营收增速更快
SRTA
高出343.8%
17.4%
自由现金流更多
LFST
多$56.8M
$-10.2M
两年增速更快
LFST
近两年复合增速
-33.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $382.2M | $22.7M |
| 净利润 | $11.7M | — |
| 毛利率 | — | -0.9% |
| 营业利润率 | 4.7% | -18.4% |
| 净利率 | 3.1% | — |
| 营收同比 | 17.4% | 361.2% |
| 净利润同比 | 264.1% | — |
| 每股收益（稀释后） | — | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LFSTSRTA
| Q4 25 | $382.2M | $22.7M | ||
| Q3 25 | $363.8M | $49.3M | ||
| Q2 25 | $345.3M | $70.8M | ||
| Q1 25 | $333.0M | $54.3M | ||
| Q4 24 | $325.5M | $-8.7M | ||
| Q3 24 | $312.7M | $36.1M | ||
| Q2 24 | $312.3M | $67.9M | ||
| Q1 24 | $300.4M | $51.5M |
净利润LFSTSRTA
| Q4 25 | $11.7M | — | ||
| Q3 25 | $1.1M | $57.4M | ||
| Q2 25 | $-3.8M | $-3.7M | ||
| Q1 25 | $709.0K | $-3.5M | ||
| Q4 24 | $-7.1M | — | ||
| Q3 24 | $-6.0M | $-2.0M | ||
| Q2 24 | $-23.3M | $-11.3M | ||
| Q1 24 | $-21.1M | $-4.2M |
毛利率LFSTSRTA
| Q4 25 | — | -0.9% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 25.1% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 19.7% |
营业利润率LFSTSRTA
| Q4 25 | 4.7% | -18.4% | ||
| Q3 25 | 2.0% | -11.4% | ||
| Q2 25 | -0.9% | -7.0% | ||
| Q1 25 | 0.5% | -14.0% | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | -19.7% | ||
| Q2 24 | -5.1% | -17.9% | ||
| Q1 24 | -5.6% | -19.2% |
净利率LFSTSRTA
| Q4 25 | 3.1% | — | ||
| Q3 25 | 0.3% | 116.5% | ||
| Q2 25 | -1.1% | -5.3% | ||
| Q1 25 | 0.2% | -6.4% | ||
| Q4 24 | -2.2% | — | ||
| Q3 24 | -1.9% | -5.4% | ||
| Q2 24 | -7.5% | -16.7% | ||
| Q1 24 | -7.0% | -8.2% |
每股收益（稀释后）LFSTSRTA
| Q4 25 | — | $-0.11 | ||
| Q3 25 | — | $0.70 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | — | $-0.03 | ||
| Q2 24 | — | $-0.15 | ||
| Q1 24 | — | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $248.6M | $31.0M |
| 总债务越低越好 | $282.8M | — |
| 股东权益账面价值 | $1.5B | $279.1M |
| 总资产 | $2.2B | $325.5M |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
现金及短期投资LFSTSRTA
| Q4 25 | $248.6M | $31.0M | ||
| Q3 25 | $203.9M | $22.8M | ||
| Q2 25 | $188.9M | $58.8M | ||
| Q1 25 | $134.3M | $34.8M | ||
| Q4 24 | $154.6M | $18.4M | ||
| Q3 24 | $102.6M | $20.0M | ||
| Q2 24 | $87.0M | $26.3M | ||
| Q1 24 | $49.5M | $36.8M |
总债务LFSTSRTA
| Q4 25 | $282.8M | — | ||
| Q3 25 | $284.6M | — | ||
| Q2 25 | $286.4M | — | ||
| Q1 25 | $288.2M | — | ||
| Q4 24 | $290.0M | — | ||
| Q3 24 | $287.3M | — | ||
| Q2 24 | $288.0M | — | ||
| Q1 24 | $288.8M | — |
股东权益LFSTSRTA
| Q4 25 | $1.5B | $279.1M | ||
| Q3 25 | $1.5B | $283.0M | ||
| Q2 25 | $1.5B | $223.1M | ||
| Q1 25 | $1.5B | $219.7M | ||
| Q4 24 | $1.4B | $221.9M | ||
| Q3 24 | $1.4B | $233.5M | ||
| Q2 24 | $1.4B | $229.4M | ||
| Q1 24 | $1.4B | $236.6M |
总资产LFSTSRTA
| Q4 25 | $2.2B | $325.5M | ||
| Q3 25 | $2.1B | $335.1M | ||
| Q2 25 | $2.1B | $257.9M | ||
| Q1 25 | $2.1B | $250.6M | ||
| Q4 24 | $2.1B | $256.7M | ||
| Q3 24 | $2.1B | $282.9M | ||
| Q2 24 | $2.1B | $280.3M | ||
| Q1 24 | $2.1B | $282.8M |
负债/权益比LFSTSRTA
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 0.20× | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.20× | — | ||
| Q1 24 | 0.20× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $57.6M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | $46.6M | $-10.2M |
| 自由现金流率自由现金流/营收 | 12.2% | -44.7% |
| 资本支出强度资本支出/营收 | 2.9% | 8.1% |
| 现金转化率经营现金流/净利润 | 4.93× | — |
| 过去12个月自由现金流最近4个季度 | $110.0M | $-58.5M |
8季度趋势，按日历期对齐
经营现金流LFSTSRTA
| Q4 25 | $57.6M | $-8.3M | ||
| Q3 25 | $27.3M | $-37.3M | ||
| Q2 25 | $64.4M | $-3.1M | ||
| Q1 25 | $-3.1M | $-246.0K | ||
| Q4 24 | $62.3M | $-1.8M | ||
| Q3 24 | $22.7M | $6.4M | ||
| Q2 24 | $44.1M | $8.4M | ||
| Q1 24 | $-21.8M | $-15.6M |
自由现金流LFSTSRTA
| Q4 25 | $46.6M | $-10.2M | ||
| Q3 25 | $17.0M | $-40.1M | ||
| Q2 25 | $56.6M | $-5.4M | ||
| Q1 25 | $-10.3M | $-2.9M | ||
| Q4 24 | $56.0M | $-6.3M | ||
| Q3 24 | $17.7M | $-3.0M | ||
| Q2 24 | $39.0M | $-7.7M | ||
| Q1 24 | $-26.9M | $-16.4M |
自由现金流率LFSTSRTA
| Q4 25 | 12.2% | -44.7% | ||
| Q3 25 | 4.7% | -81.4% | ||
| Q2 25 | 16.4% | -7.6% | ||
| Q1 25 | -3.1% | -5.3% | ||
| Q4 24 | 17.2% | 72.7% | ||
| Q3 24 | 5.7% | -8.2% | ||
| Q2 24 | 12.5% | -11.4% | ||
| Q1 24 | -9.0% | -31.8% |
资本支出强度LFSTSRTA
| Q4 25 | 2.9% | 8.1% | ||
| Q3 25 | 2.8% | 5.7% | ||
| Q2 25 | 2.2% | 3.2% | ||
| Q1 25 | 2.2% | 4.8% | ||
| Q4 24 | 1.9% | -52.6% | ||
| Q3 24 | 1.6% | 25.8% | ||
| Q2 24 | 1.6% | 23.8% | ||
| Q1 24 | 1.7% | 1.6% |
现金转化率LFSTSRTA
| Q4 25 | 4.93× | — | ||
| Q3 25 | 25.34× | -0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | -4.36× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LFST
暂无分部数据
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
